MDSCs in cancer: Conceiving new prognostic and therapeutic targets

Francesco De Sanctis, Samantha Solito, Stefano Ugel, Barbara Molon, Vincenzo Bronte, Ilaria Marigo

Research output: Contribution to journalArticlepeer-review


The incomplete clinical efficacy of anti-tumor immunotherapy can depend on the presence of an immunosuppressive environment in the host that supports tumor progression. Tumor-derived cytokines and growth factors induce an altered hematopoiesis that modifies the myeloid cell differentiation process, promoting proliferation and expansion of cells with immunosuppressive skills, namely myeloid derived suppressor cells (MDSCs). MDSCs promote tumor growth not only by shaping immune responses towards tumor tolerance, but also by supporting several processes necessary for the neoplastic progression such as tumor angiogenesis, cancer stemness, and metastasis dissemination. Thus, MDSC targeting represents a promising tool to eliminate host immune dysfunctions and increase the efficacy of immune-based cancer therapies.

Original languageEnglish
Pages (from-to)35-48
Number of pages14
JournalBiochimica et Biophysica Acta - Reviews on Cancer
Issue number1
Publication statusPublished - Jan 1 2016


  • Cancer-microenvironment
  • MDSC-targeting approach
  • Myeloid-derived suppressor cells

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics


Dive into the research topics of 'MDSCs in cancer: Conceiving new prognostic and therapeutic targets'. Together they form a unique fingerprint.

Cite this